Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Increlex extension study in children and adolescents with primary IGF-1 deficiency
2019-000844-81Phase 3
- Sponsor
- Ipsen
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mecasermin in insulin-like growth factor 1 deficiency and faltering growth (FTT), sponsored by Ipsen. Primary endpoint: Height velocity.
02
Drugs
mecasermin
03
Conditions
insulin-like growth factor 1 deficiencyfaltering growth (FTT)
Beyond the preview
Go deeper on 2019-000844-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000844-81.